Your browser doesn't support javascript.
loading
Use of Closed System Transfer Devices (CSTDs) with Protein-Based Therapeutic Drugs-A Non-Solution for a Non-Problem?
Fast, Jonas; Christian, Twinkle; Crul, Mirjam; Jiskoot, Wim; Nejadnik, M Reza; Medina, Annette; Radwick, Allison; Sreedhara, Alavattam; Tole, Hugh.
Afiliação
  • Fast J; Pharmaceutical Development, F. Hoffmann-La Roche Ltd. CH-4070 Basel, Switzerland. Electronic address: jonas.fast@roche.com.
  • Christian T; Process Development, Amgen, Thousand Oaks, CA, USA.
  • Crul M; Amsterdam University Medical Center, Department of Clinical Pharmacology and Pharmacy, Amsterdam, the Netherlands.
  • Jiskoot W; Division of BioTherapeutics, Leiden University, the Netherlands; Coriolis Pharma, Martinsried, Germany.
  • Nejadnik MR; Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.
  • Medina A; Dosage Form Design and Development, AstraZeneca, Gaithersburg, MD, USA.
  • Radwick A; United States Pharmacopeia, Rockville, MD, USA.
  • Sreedhara A; Pharmaceutical Development, Genentech, South San Francisco, CA, USA.
  • Tole H; Occupational Health, Hygiene &Toxicology, Genentech Inc., Little Falls, NJ, USA.
J Pharm Sci ; 113(2): 298-305, 2024 02.
Article em En | MEDLINE | ID: mdl-37984700
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Exposição Ocupacional / Imunoconjugados / Antineoplásicos Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Exposição Ocupacional / Imunoconjugados / Antineoplásicos Idioma: En Ano de publicação: 2024 Tipo de documento: Article